

Joel M Kremer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/801616/publications.pdf>

Version: 2024-02-01

204
papers

24,506
citations

15880

67
h-index

8034

154
g-index

207
all docs

207
docs citations

207
times ranked

14611
citing authors

#	ARTICLE	IF	CITATIONS
1	TNFi Cycling Versus Changing Mechanism of Action in TNFi-Experienced Patients: Result of the Corona CERTAIN Comparative Effectiveness Study. <i>ACR Open Rheumatology</i> , 2022, 4, 65-73.	0.9	7
2	Obesity and Response to Advanced Therapies in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 1909-1916.	1.5	9
3	Perspectives on applying immuno-autonomics to rheumatoid arthritis: results from an online rheumatologist survey. <i>Rheumatology International</i> , 2022, 42, 1555-1564.	1.5	1
4	Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1114-1124.	1.5	10
5	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.5	158
6	Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study. <i>Rheumatology International</i> , 2021, 41, 585-593.	1.5	4
7	Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corona Rheumatoid Arthritis Registry. <i>Rheumatology and Therapy</i> , 2021, 8, 467-481.	1.1	0
8	Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis. <i>International Immunopharmacology</i> , 2021, 91, 107260.	1.7	4
9	Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry. <i>ACR Open Rheumatology</i> , 2021, 3, 173-184.	0.9	88
10	Methotrexate and Cardiovascular Disease in Patients With Rheumatoid Arthritis: Insights and Novel Speculations. <i>Journal of Rheumatology</i> , 2021, 48, 793-795.	1.0	1
11	A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor- \pm Inhibitors: The NETWORK-004 Prospective Observational Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1159-1176.	1.1	16
12	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 924-939.	1.5	466
13	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1108-1123.	2.9	339
14	Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1522-1529.	0.5	46
15	Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 831-838.	1.6	26
16	Dr. Kremer et al reply. <i>Journal of Rheumatology</i> , 2021, , jrheum.210992.	1.0	0
17	Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy. <i>Journal of Rheumatology</i> , 2020, 47, 325-332.	1.0	2
18	Weight Fluctuation and the Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, , .	1.5	3

#	ARTICLE	IF	CITATIONS
19	Methotrexate Pulmonary Toxicity: Deep Inspiration. <i>Arthritis and Rheumatology</i> , 2020, 72, 1959-1962.	2.9	9
20	Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2020, 7, 775-792.	1.1	19
21	Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. <i>RMD Open</i> , 2020, 6, e001370.	1.8	23
22	The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies. <i>Journal of Rheumatology</i> , 2020, 48, jrheum.200692.	1.0	9
23	External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti-inflammatory Drug Users: Real-World Application. <i>ACR Open Rheumatology</i> , 2020, 2, 269-275.	0.9	0
24	Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren's syndrome enrolled in a large observational US registry. <i>Rheumatology International</i> , 2020, 40, 1239-1248.	1.5	8
25	Physician Prescribing Patterns and Risk of Future Long-Term Opioid Use Among Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 1082-1090.	2.9	8
26	Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry. <i>Rheumatology and Therapy</i> , 2020, 7, 357-369.	1.1	4
27	Patient Perception of Cardiovascular Risk in Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2020, 2, 255-260.	0.9	5
28	Hydroxychloroquine and the risk of respiratory infections among RA patients. <i>RMD Open</i> , 2020, 6, e001389.	1.8	4
29	Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 848-857.	0.4	6
30	Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers. <i>Arthritis and Rheumatology</i> , 2019, 71, 1987-1996.	2.9	87
31	Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2019, 6, 573-586.	1.1	29
32	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 878-891.	2.9	64
33	Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. <i>PLoS ONE</i> , 2019, 14, e0210459.	1.1	31
34	Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. <i>Journal of Rheumatology</i> , 2019, 46, 475-482.	1.0	31
35	Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice. <i>Rheumatology and Therapy</i> , 2019, 6, 421-433.	1.1	1
36	Outcomes of infliximab dose escalation in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 2501-2508.	1.0	2

#	ARTICLE	IF	CITATIONS
37	Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry. <i>Rheumatology and Therapy</i> , 2019, 6, 217-230.	1.1	18
38	FRI0155â€¦A COMPARISON OF UPADACITINIB PLUS METHOTREXATE AND UPADACITINIB PLUS OTHER CSDMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN ANALYSIS OF TWO PHASE 3 STUDIES. , 2019, , .		0
39	OP0028â€¦POST-APPROVAL COMPARATIVE SAFETY STUDY OF TOFACITINIB AND BIOLOGIC DMARDS: FIVEâ€“YEAR RESULTS FROM A US-BASED RHEUMATOID ARTHRITIS REGISTRY. , 2019, , .		9
40	Chronic Opioid Use in Rheumatoid Arthritis: Prevalence and Predictors. <i>Arthritis and Rheumatology</i> , 2019, 71, 670-677.	2.9	49
41	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 988-995.	0.5	41
42	Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab. <i>Arthritis and Rheumatology</i> , 2018, 70, 1200-1208.	2.9	39
43	Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 900-908.	0.9	47
44	Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. <i>Clinical Rheumatology</i> , 2018, 37, 2331-2340.	1.0	22
45	242â€“A phase III randomised placebo-controlled double-blind study of upadacitinib (ABT-494), a selective JAK-1 Inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic DMARDs. <i>Rheumatology</i> , 2018, 57, .	0.9	1
46	Design characteristics of the Corrona Japan rheumatoid arthritis registry. <i>Modern Rheumatology</i> , 2018, 28, 95-100.	0.9	2
47	Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-Î± Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study. <i>Journal of Rheumatology</i> , 2018, 45, 32-39.	1.0	42
48	Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 472-477.	1.6	19
49	Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis. <i>Chinese Medical Journal</i> , 2018, 131, 2683-2692.	0.9	28
50	Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2018, 5, 507-523.	1.1	11
51	e48â€“Effects of baricitinib on haematological laboratory parameters in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, .	0.9	3
52	Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry. <i>Journal of Rheumatology</i> , 2018, 45, 1353-1360.	1.0	7
53	Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate. <i>Open Access Rheumatology: Research and Reviews</i> , 2018, Volume 10, 97-101.	0.8	3
54	One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry. <i>Arthritis Research and Therapy</i> , 2018, 20, 2.	1.6	21

#	ARTICLE	IF	CITATIONS
55	Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 2275-2280.	1.0	5
56	Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , 2018, 391, 2503-2512.	6.3	280
57	Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry. <i>American Health and Drug Benefits</i> , 2018, 11, 148-158.	0.5	7
58	The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 310-319.	0.9	19
59	A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1020-1030.	0.5	117
60	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 694-700.	0.5	83
61	Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 165-169.	1.6	10
62	A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?. <i>Clinical Rheumatology</i> , 2017, 36, 1215-1220.	1.0	16
63	Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1751-1761.	2.9	65
64	Fish Oil and Inflammation – A Fresh Look. <i>Journal of Rheumatology</i> , 2017, 44, 713-716.	1.0	3
65	Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 943-952.	2.9	42
66	Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry. <i>Rheumatology and Therapy</i> , 2017, 4, 489-502.	1.1	51
67	Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry. <i>Rheumatology and Therapy</i> , 2017, 4, 375-389.	1.1	12
68	Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2017, 4, 405-417.	1.1	13
69	Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry. <i>Clinical Rheumatology</i> , 2017, 36, 2135-2140.	1.0	11
70	Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2017, 69, 592-598.	1.5	62
71	Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. <i>RMD Open</i> , 2016, 2, e000287.	1.8	46
72	Baricitinib in Patients with Refractory Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2016, 374, 1243-1252.	13.9	499

#	ARTICLE	IF	CITATIONS
73	Gout Prophylaxis Evaluated According to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry. <i>Journal of Rheumatology</i> , 2016, 43, 924-930.	1.0	8
74	A Phase IIb Study of ABT494, a Selective JAK1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. <i>Arthritis and Rheumatology</i> , 2016, 68, 2867-2877.	2.9	149
75	Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 1216-1225.	0.9	26
76	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12460.	5.8	73
77	Bias? Not so fast. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1581-1582.	0.5	2
78	Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. <i>Arthritis Research and Therapy</i> , 2016, 18, 280.	1.6	23
79	Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry. <i>Journal of Rheumatology</i> , 2016, 43, 1027-1029.	1.0	12
80	Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry. <i>Rheumatology and Therapy</i> , 2016, 3, 103-115.	1.1	8
81	Association analysis of copy numbers of FC-gamma receptor genes for rheumatoid arthritis and other immune-mediated phenotypes. <i>European Journal of Human Genetics</i> , 2016, 24, 263-270.	1.4	25
82	Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 625-33.	0.4	18
83	Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 430-42.	0.4	23
84	The Corrona US registry of rheumatic and autoimmune diseases. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S96-S99.	0.4	23
85	Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based Registry. <i>Rheumatology and Therapy</i> , 2015, 2, 153-164.	1.1	8
86	Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs. <i>Arthritis Care and Research</i> , 2015, 67, 1671-1678.	1.5	67
87	Can Methotrexate Prevent Knee Arthroplasties in Patients with Rheumatoid Arthritis?. <i>Journal of Rheumatology</i> , 2015, 42, 2217-2218.	1.0	3
88	Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. <i>Arthritis Research and Therapy</i> , 2015, 17, 307.	1.6	53
89	Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study. <i>RMD Open</i> , 2015, 1, e000037.	1.8	17
90	Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and Ninja Collaborative Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 2238-2246.	1.0	14

#	ARTICLE	IF	CITATIONS
91	Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. <i>Arthritis Research and Therapy</i> , 2015, 17, 95.	1.6	46
92	The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 430-436.	0.5	61
93	Subcutaneous nodules are associated with cardiovascular events in patients with rheumatoid arthritis: results from a large US registry. <i>Clinical Rheumatology</i> , 2015, 34, 1697-1704.	1.0	12
94	Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry. <i>Journal of Rheumatology</i> , 2015, 42, 1090-1098.	1.0	21
95	A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 170-176.	0.5	55
96	Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. <i>Arthritis Research and Therapy</i> , 2015, 17, 256.	1.6	46
97	Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 163-166.	1.6	12
98	TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits. <i>PLoS ONE</i> , 2015, 10, e0122271.	1.1	120
99	Longterm Safety, Efficacy, and Inhibition of Structural Damage Progression Over 5 Years of Treatment with Abatacept in Patients with Rheumatoid Arthritis in the Abatacept in Inadequate Responders to Methotrexate Trial. <i>Journal of Rheumatology</i> , 2014, 41, 1077-1087.	1.0	29
100	New EULAR guidelines for RA: a job well done. <i>Nature Reviews Rheumatology</i> , 2014, 10, 6-8.	3.5	3
101	Still Trying to Understand Methotrexate. <i>Journal of Rheumatology</i> , 2014, 41, 2099-2101.	1.0	3
102	Use of health plan combined with registry data to predict clinical trial recruitment. <i>Clinical Trials</i> , 2014, 11, 96-101.	0.7	7
103	Applying biologic therapies to the management of patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 577.	1.6	2
104	Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 489-497.	1.6	99
105	Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 113.	0.8	26
106	Linkage of a Deidentified United States Rheumatoid Arthritis Registry With Administrative Data to Facilitate Comparative Effectiveness Research. <i>Arthritis Care and Research</i> , 2014, 66, 1790-1798.	1.5	65
107	Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2013, 159, 253.	2.0	381
108	Racial and Ethnic Disparities in Disease Activity in Patients with Rheumatoid Arthritis. <i>American Journal of Medicine</i> , 2013, 126, 1089-1098.	0.6	90

#	ARTICLE	IF	CITATIONS
109	Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. <i>Rheumatology</i> , 2013, 52, 1809-1817.	0.9	101
110	Tofacitinib (CPâ€690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelveâ€month data from a twentyâ€fourâ€month phase III randomized radiographic study. <i>Arthritis and Rheumatism</i> , 2013, 65, 559-570.	6.7	481
111	Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results. <i>Journal of Rheumatology</i> , 2013, 40, 113-126.	1.0	87
112	Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. <i>Journal of Rheumatology</i> , 2013, 40, 768-780.	1.0	108
113	Association of Rheumatoid Arthritis Risk Alleles with Response to Anti-TNF Biologics: Results from the CORRONA Registry and Meta-analysis. <i>Inflammation</i> , 2013, 36, 279-284.	1.7	16
114	Comparative Effectiveness of Nonbiologic versus Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 127-136.	1.0	6
115	Tocilizumab as monotherapy or in combination with nonbiologic diseaseâ€modifying antirheumatic drugs: Twentyâ€fourâ€week results of an openâ€label, clinical practice study. <i>Arthritis Care and Research</i> , 2013, 65, 362-371.	1.5	56
116	Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 908-910.	0.5	25
117	Multiple Courses of Rituximab Produce Sustained Clinical and Radiographic Efficacy and Safety in Patients with Rheumatoid Arthritis and an Inadequate Response to 1 or More Tumor Necrosis Factor Inhibitors: 5-Year Data from the REFLEX Study. <i>Journal of Rheumatology</i> , 2012, 39, 2238-2246.	1.0	65
118	Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of north america cohort of rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2012, 64, 1811-1818.	1.5	38
119	Malignancy validation in a United States registry of rheumatoid arthritis patients. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 85.	0.8	7
120	A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1134-1142.	0.5	136
121	Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 495-507.	13.9	826
122	A phase IIb doseâ€ranging study of the oral JAK inhibitor tofacitinib (CPâ€690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. <i>Arthritis and Rheumatism</i> , 2012, 64, 970-981.	6.7	293
123	2012 Update of the 2008 American College of Rheumatology recommendations for the use of diseaseâ€modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 625-639.	1.5	1,413
124	Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 1-9.	0.7	38
125	Integrated safety in tocilizumab clinical trials. <i>Arthritis Research and Therapy</i> , 2011, 13, R141.	1.6	278
126	Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry. <i>Arthritis Care and Research</i> , 2011, 63, 856-864.	1.5	49

#	ARTICLE	IF	CITATIONS
127	Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort. <i>Arthritis Care and Research</i> , 2011, 63, 1672-1679.	1.5	43
128	Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu. <i>Arthritis and Rheumatism</i> , 2011, 63, 609-621.	6.7	369
129	Maintenance of Efficacy and Safety with Subcutaneous Golimumab Among Patients with Active Rheumatoid Arthritis Who Previously Received Intravenous Golimumab. <i>Journal of Rheumatology</i> , 2011, 38, 2572-2580.	1.0	9
130	Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 576-582.	0.5	304
131	Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1826-1830.	0.5	134
132	A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 2-14.e1.	1.6	161
133	Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2010, 62, 917-928.	6.7	116
134	Methotrexate polyglutamate concentrations and association with disease control in rheumatoid arthritis: Comment on the article by Stamp et al. <i>Arthritis and Rheumatism</i> , 2010, 62, 2559-2560.	6.7	2
135	Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1612-1617.	0.5	89
136	Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. <i>Rheumatology</i> , 2010, 49, 2337-2345.	0.9	71
137	Comparative Analysis of Disease Activity Measures, Use of Biologic Agents, Body Mass Index, Radiographic Features, and Bone Density in Psoriatic Arthritis and Rheumatoid Arthritis Patients Followed in a Large U.S. Disease Registry. <i>Journal of Rheumatology</i> , 2010, 37, 2566-2572.	1.0	31
138	Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1920-1925.	0.5	255
139	Etanercept for patients with RA: more is not always better. <i>Nature Clinical Practice Rheumatology</i> , 2009, 5, 10-11.	3.2	1
140	Utilization Trends of Tumor Necrosis Factor Inhibitors Among Patients with Rheumatoid Arthritis in a United States Observational Cohort Study. <i>Journal of Rheumatology</i> , 2009, 36, 1611-1617.	1.0	60
141	Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2009, 48, 686-690.	0.9	26
142	The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP690,550 versus placebo. <i>Arthritis and Rheumatism</i> , 2009, 60, 1895-1905.	6.7	501
143	Interpreting registry-derived drug studies: Does societal context matter?. <i>Arthritis and Rheumatism</i> , 2009, 60, 3155-3157.	6.7	11
144	Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study. <i>Journal of Rheumatology</i> , 2009, 36, 736-742.	1.0	114

#	ARTICLE	IF	CITATIONS
145	Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 935-944.	0.7	51
146	Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. <i>Arthritis and Rheumatism</i> , 2008, 58, 953-963.	6.7	159
147	Methotrexate treatment of rheumatic diseases: Can we do better?. <i>Arthritis and Rheumatism</i> , 2008, 58, 3279-3282.	6.7	16
148	Tumor Necrosis Factor Antagonist Responsiveness in a United States Rheumatoid Arthritis Cohort. <i>American Journal of Medicine</i> , 2008, 121, 532-538.	0.6	32
149	COMET's path, and the new biologicals in rheumatoid arthritis. <i>Lancet, The</i> , 2008, 372, 347-348.	6.3	4
150	The role of drug and disease registries in rheumatic disease epidemiology. <i>Current Opinion in Rheumatology</i> , 2008, 20, 123-130.	2.0	25
151	Does DMARD treatment slow or prevent development of RA in patients with UA?. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 690-691.	3.2	0
152	Rheumatoid arthritis: a rapidly evolving treatment paradigm. <i>Managed Care Interface</i> , 2007, 20, 17, 24.	0.2	0
153	Rheumatoid arthritis—is methotrexate re-employment an effective treatment option?. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 246-247.	3.2	0
154	Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2006, 144, 865.	2.0	643
155	The CORRONA database. <i>Autoimmunity Reviews</i> , 2006, 5, 46-54.	2.5	63
156	Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 607-612.	6.7	148
157	Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 3095-3103.	6.7	188
158	Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 228-234.	0.5	261
159	Selective Costimulation Modulators. <i>Journal of Clinical Rheumatology</i> , 2005, 11, S55-S62.	0.5	37
160	Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. <i>Arthritis and Rheumatism</i> , 2005, 53, 12-17.	6.7	27
161	Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 2263-2271.	6.7	456
162	Is the outcome of rheumatoid arthritis changed with the use of new disease-modifying antirheumatic drugs?. <i>Arthritis and Rheumatism</i> , 2005, 53, 636-638.	6.7	0

#	ARTICLE	IF	CITATIONS
163	Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor $\hat{\pm}$ Inhibition. <i>New England Journal of Medicine</i> , 2005, 353, 1114-1123.	13.9	1,157
164	Toward a better understanding of methotrexate. <i>Arthritis and Rheumatism</i> , 2004, 50, 1370-1382.	6.7	432
165	Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 2766-2774.	6.7	312
166	Cytotoxic T-lymphocyte antigen 4 $\hat{\pm}$ immunoglobulin in rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 381-391.	0.8	16
167	Treatment of rheumatoid arthritis with etanercept. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 311-328.	0.8	25
168	Leflunomide. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 295-309.	0.8	39
169	Contribution of common polymorphisms in reduced folate carrier and ??-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 733-739.	5.7	155
170	Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. <i>Journal of Rheumatology</i> , 2004, 31, 1521-31.	1.0	65
171	New and emerging therapies for rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, xi-xii.	0.8	0
172	Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: Continued observations. <i>Arthritis and Rheumatism</i> , 2003, 48, 1493-1499.	6.7	97
173	Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate. <i>Arthritis and Rheumatism</i> , 2003, 48, 2763-2768.	6.7	56
174	Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig. <i>New England Journal of Medicine</i> , 2003, 349, 1907-1915.	13.9	973
175	Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of Methotrexate. <i>Annals of Internal Medicine</i> , 2002, 137, 726.	2.0	287
176	Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2002, 46, 614-624.	6.7	570
177	Rational Use of New and Existing Disease-Modifying Agents in Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2001, 134, 695.	2.0	165
178	n $\hat{\sim}$ 3 Fatty acid supplements in rheumatoid arthritis. <i>American Journal of Clinical Nutrition</i> , 2000, 71, 349S-351S.	2.2	240
179	Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 1322-1328.	6.7	248
180	A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate. <i>New England Journal of Medicine</i> , 1999, 340, 253-259.	13.9	2,044

#	ARTICLE	IF	CITATIONS
181	Treatment of rheumatoid arthritis with oral type II collagen: Results of a multicenter, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 1998, 41, 290-297.	6.7	206
182	Combination therapy with biologic agents in rheumatoid arthritis: Perils and promise. <i>Arthritis and Rheumatism</i> , 1998, 41, 1548-1551.	6.7	35
183	Long-term exposure to methotrexate induces immunophenotypic changes, decreased methotrexate uptake and increased dihydrofolate gene copy number in jurkat T cells. <i>International Journal of Immunopharmacology</i> , 1998, 19, 709-720.	1.1	6
184	Xanthomatous infiltration of ankle tendons. <i>Skeletal Radiology</i> , 1997, 26, 256-259.	1.2	15
185	Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: Followup after a mean of 13.3 years. <i>Arthritis and Rheumatism</i> , 1997, 40, 984-985.	6.7	91
186	Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis. A multicenter study with literature review. <i>Arthritis and Rheumatism</i> , 1997, 40, 1829-1837.	6.7	279
187	Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n-3 and n-6 fatty acids. <i>Lipids</i> , 1996, 31, S243-S247.	0.7	86
188	Every-other-week methotrexate in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 601-607.	6.7	17
189	Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs clinical and immune correlates. <i>Arthritis and Rheumatism</i> , 1995, 38, 1107-1114.	6.7	224
190	Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy followup over long treatment intervals and correlation with clinical and laboratory variables. <i>Arthritis and Rheumatism</i> , 1995, 38, 1194-1203.	6.7	65
191	Methotrexate for Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 1994, 37, 316-328.	6.7	594
192	Lack of a renal "protective effect of misoprostol in rheumatoid arthritis patients receiving cyclosporin a. results of a randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 1994, 37, 1321-1325.	6.7	8
193	Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 329-335.	6.7	187
194	Long-Term Prospective Study of the Use of Methotrexate in the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 1992, 35, 138-145.	6.7	252
195	Dietary fish oil and olive oil supplementation in patients with Rheumatoid Arthritis clinical and immunologic effects. <i>Arthritis and Rheumatism</i> , 1990, 33, 810-820.	6.7	502
196	Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A Prospective Study with Baseline and Sequential Biopsy Samples. <i>Arthritis and Rheumatism</i> , 1989, 32, 121-127.	6.7	178
197	Electron microscopic analysis of sequential liver biopsy samples from patients with rheumatoid arthritis. Correlation with light microscopic findings. <i>Arthritis and Rheumatism</i> , 1989, 32, 1202-1213.	6.7	22
198	Methotrexate in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1988, 31, 305-314.	6.7	168

#	ARTICLE	IF	CITATIONS
199	A long-term prospective study of the use of methotrexate in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1988, 31, 577-584.	6.7	147
200	Fish-Oil Fatty Acid Supplementation in Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 1987, 106, 497.	2.0	508
201	Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. <i>American Journal of Medicine</i> , 1987, 82, 781-786.	0.6	113
202	Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate. <i>Arthritis and Rheumatism</i> , 1987, 30, 369-374.	6.7	22
203	The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1986, 29, 822-831.	6.7	379
204	Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: Association with hepatic folate deficiency and formation of polyglutamates. <i>Arthritis and Rheumatism</i> , 1986, 29, 832-835.	6.7	207